Related Experiment Video

Updated: Sep 30, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K

Future Treatment Options in Systemic Sclerosis-Potential Targets and Ongoing Clinical Trials

Anna Bohdziewicz1, Katarzyna Karina Pawlik1, Magdalena Maciejewska1

  • 1Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland.

Journal of Clinical Medicine
|March 10, 2022
PubMed

Insights

New treatments targeting immune mediators show promise for systemic sclerosis, a complex autoimmune disease. Clinical trials are exploring novel therapies to halt disease progression and improve patient outcomes.

Area of Science:

  • Immunology and Rheumatology
  • Autoimmune Diseases
  • Fibrotic Conditions

Background:

  • Systemic sclerosis is a complex autoimmune connective tissue disease marked by vasculopathy and fibrosis.
  • Current treatments for systemic sclerosis are often insufficient to halt disease progression.
  • Immune cell mediators play a key role in the inflammatory processes of systemic sclerosis.

Purpose of the Study:

  • To provide an overview of potential therapeutic targets for systemic sclerosis.
  • To review the pipeline of future therapeutic options based on ongoing clinical trials.
  • To highlight novel treatment strategies for managing systemic sclerosis.

Main Methods:

  • Review of clinical trials investigating novel, unestablished treatment methods for systemic sclerosis.
  • Identification of therapeutic targets based on increasing knowledge of disease pathogenesis.
  • Analysis of drug trials targeting specific mediators and pathways involved in systemic sclerosis.

Main Results:

  • Numerous drug trials are underway targeting key mediators such as CD28-CD80/86, CD19, CCL24, CD20, CD30, tumor necrosis factor (TNF), transforming growth factor β (TGF-β), B-cell activating factor (BAFF), lysophosphatidic acid receptor 1 (LPA1 receptor), soluble guanylate cyclase (sGC), Janus kinases (JAK), interleukin 6 (IL-6), endothelin receptor, and autotaxin.
  • Early data from these clinical trials suggest significant potential for several new therapeutic options.
  • Advancements in understanding disease processes are driving the development of targeted therapies.

Conclusions:

  • Emerging therapeutic targets and ongoing clinical trials offer significant hope for improved systemic sclerosis treatment.
  • Novel therapies targeting specific immune pathways and mediators show promise in halting disease progression.
  • The future pipeline for systemic sclerosis treatment is robust, with multiple promising options on the horizon.
Keywords:
SAR100842belimumabbrentuximab vedotinimatinibnilotinibnintedanibriociguatrituximabsystemic sclerosistofacitinib

More Related Videos

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.2K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

419

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
232
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K